- Home
- EXAS vs RVMD Comparison
EXAS vs RVMD Comparison
Compare EXAS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- RVMD
- Stock Information
- Founded
- EXAS 1995
- RVMD 2014
- Country
- EXAS United States
- RVMD United States
- Employees
- EXAS N/A
- RVMD N/A
- Industry
- EXAS Medical Specialities
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EXAS Health Care
- RVMD Health Care
- Exchange
- EXAS Nasdaq
- RVMD Nasdaq
- Market Cap
- EXAS 10.5B
- RVMD 8.7B
- IPO Year
- EXAS N/A
- RVMD 2020
- Fundamental
- Price
- EXAS $51.74
- RVMD $40.29
- Analyst Decision
- EXAS Strong Buy
- RVMD Strong Buy
- Analyst Count
- EXAS 16
- RVMD 13
- Target Price
- EXAS $72.80
- RVMD $65.15
- AVG Volume (30 Days)
- EXAS 2.2M
- RVMD 1.3M
- Earning Date
- EXAS 02-19-2025
- RVMD 02-24-2025
- Dividend Yield
- EXAS N/A
- RVMD N/A
- EPS Growth
- EXAS N/A
- RVMD N/A
- EPS
- EXAS N/A
- RVMD N/A
- Revenue
- EXAS $2,692,328,000.00
- RVMD $742,000.00
- Revenue This Year
- EXAS $11.81
- RVMD N/A
- Revenue Next Year
- EXAS $11.52
- RVMD $1,855.42
- P/E Ratio
- EXAS N/A
- RVMD N/A
- Revenue Growth
- EXAS 11.91
- RVMD N/A
- 52 Week Low
- EXAS $40.62
- RVMD $26.25
- 52 Week High
- EXAS $79.62
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- EXAS 35.28
- RVMD 31.69
- Support Level
- EXAS $49.79
- RVMD $39.48
- Resistance Level
- EXAS $60.88
- RVMD $42.97
- Average True Range (ATR)
- EXAS 2.67
- RVMD 1.48
- MACD
- EXAS -0.59
- RVMD -0.11
- Stochastic Oscillator
- EXAS 17.58
- RVMD 14.05
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.